Besides, there was another clinical trial that aimed at the efficacy and adverse events of CD19/CD22 CAR-T cell therapy for aggressive B-cell lymphoma involving gastrointestinal tract. Here, CD22 is linked to B-cell non-Hodgkin lymphoma.